Dr. Naomi Ko, MD
Claim this profileBoston Medical Center
Studies Breast Cancer
Studies Cancer
5 reported clinical trials
11 drugs studied
Area of expertise
1Breast Cancer
HER2 positive
ER positive
Stage IV
2Cancer
HER2 positive
ER positive
ER negative
Affiliated Hospitals
Clinical Trials Naomi Ko, MD is currently running
Chemotherapy Reduction After Surgery
for Breast Cancer
This trial studies how well paclitaxel, trastuzumab, and pertuzumab work in eliminating further chemotherapy after surgery in patients with HER2-positive stage II-IIIa breast cancer who have no cancer remaining at surgery (either in the breast or underarm lymph nodes) after pre-operative chemotherapy and HER2-targeted therapy. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Trastuzumab and pertuzumab are both a form of "targeted therapy" because they work by attaching themselves to specific molecules (receptors) on the surface of tumor cells, known as HER2 receptors. When these drugs attach to HER2 receptors, the signals that tell the cells to grow are blocked and the tumor cell may be marked for destruction by the body's immune system. Giving paclitaxel, trastuzumab, and pertuzumab may enable fewer chemotherapy drugs to be given without compromising patient outcomes compared to the usual treatment.
Recruiting1 award Phase 227 criteria
Sacituzumab Govitecan + Talazoparib
for Breast Cancer
This research is studying the effect of Antibody-Drug Conjugate Sacituzumab Govitecan in Combination with the Poly (Adenosine Diphosphate \[ADP\]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients with Metastatic Triple-Negative Breast Cancer.
Recruiting3 awards Phase 1 & 211 criteria
More about Naomi Ko, MD
Clinical Trial Related4 years of experience running clinical trials · Led 5 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Naomi Ko, MD has experience with
- Sacituzumab Govitecan
- Talazoparib
- Palbociclib
- Avelumab
- Fulvestrant
- Diffuse Optical Spectroscopy Imaging (DOSI)
Breakdown of trials Naomi Ko, MD has run
Breast Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Naomi Ko, MD specialize in?
Naomi Ko, MD focuses on Breast Cancer and Cancer. In particular, much of their work with Breast Cancer has involved HER2 positive patients, or patients who are ER positive.
Is Naomi Ko, MD currently recruiting for clinical trials?
Yes, Naomi Ko, MD is currently recruiting for 3 clinical trials in Boston Massachusetts. If you're interested in participating, you should apply.
Are there any treatments that Naomi Ko, MD has studied deeply?
Yes, Naomi Ko, MD has studied treatments such as Sacituzumab Govitecan, Talazoparib, Palbociclib.
What is the best way to schedule an appointment with Naomi Ko, MD?
Apply for one of the trials that Naomi Ko, MD is conducting.
What is the office address of Naomi Ko, MD?
The office of Naomi Ko, MD is located at: Boston Medical Center, Boston, Massachusetts 02118 United States. This is the address for their practice at the Boston Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.